Dihydroquercetin · DHQ · Distylin
100 mg · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Taxifolin (dihydroquercetin, DHQ) is the reduced form of quercetin, lacking the C2–C3 double bond. This structural difference makes it more stable, more water-soluble, and potentially more bioavailable than quercetin. It occurs naturally in onions, milk thistle, and Douglas fir bark.
Taxifolin scavenges hydroxyl and superoxide radicals, inhibits lipid peroxidation, and protects capillary integrity by reducing vascular permeability. It modulates NF-κB and MAPK pathways to reduce pro-inflammatory cytokines. Unlike quercetin, taxifolin does not form potentially mutagenic quinone metabolites and has a cleaner safety profile at high doses.
Adults seeking capillary and vascular antioxidant support, or those who want flavonoid benefits with potentially better bioavailability than quercetin.
No major contraindications. May mildly inhibit CYP3A4 and CYP2C9 at high doses. Those on medications metabolized by these enzymes should consult a physician.
✓ Can be split across meals for sustained antioxidant coverage
✓ Can be split across meals for sustained antioxidant coverage
✓ Take with meals to improve absorption of this polyphenol
Taxifolin scavenges hydroxyl and superoxide radicals, inhibits lipid peroxidation, and protects capillary integrity by reducing vascular permeability.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Representative cohort from published RCT data
Relative to baseline (100). Data from published clinical literature.
In vitro + in vivo
→ Taxifolin significantly reduced VEGF-induced capillary permeability in endothelial cell monolayers and decreased paw edema in carrageenan-induced inflammation models via NF-κB and MAPK pathway modulation
Rodent model
→ Dihydroquercetin attenuated cardiac hypertrophy, fibrosis, and dysfunction in pressure overload-induced heart failure models, reducing oxidative stress and inflammatory markers
Review
→ Review of taxifolin's superior stability over quercetin, better water solubility, and lack of quinone-type mutagenic metabolites. Noted anti-inflammatory, antidiabetic, and hepatoprotective potential
B · Strong preclinical data for capillary protection and cardiovascular remodeling. More stable and water-soluble than quercetin. Human clinical trials are limited but the safety profile appears cleaner than quercetin at equivalent doses
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: Abenavoli 2010 (hepatoprotection systematic review), Cacciapuoti 2013 (NAFLD RCT). richResearch section contains study filters.
How to use Taxifolin specifically for Capillary fragility — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of Taxifolin — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about Taxifolin — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on Taxifolin — context the structured blocks above don't capture.
Taxifolin (dihydroquercetin, DHQ) is the reduced form of quercetin, lacking the C2–C3 double bond. This structural difference makes it more stable, more water-soluble, and potentially more bioavailable than quercetin. It occurs naturally in onions, milk thistle, and Douglas fir bark.
Taxifolin scavenges hydroxyl and superoxide radicals, inhibits lipid peroxidation, and protects capillary integrity by reducing vascular permeability. It modulates NF-κB and MAPK pathways to reduce pro-inflammatory cytokines. Unlike quercetin, taxifolin does not form potentially mutagenic quinone metabolites and has a cleaner safety profile at high doses.
Who benefits most
Adults seeking capillary and vascular antioxidant support, or those who want flavonoid benefits with potentially better bioavailability than quercetin.
Dosage and form
100 mg is the typical effective range. Forms matter: choose standardised extracts or highly bioavailable delivery formats (see the Forms tab). Take as directed.
Side effects and cautions
Generally well-tolerated. Mild GI upset possible in sensitive users. Rare allergic reactions in those sensitive to the plant family. Avoid if you: No major contraindications. May mildly inhibit CYP3A4 and CYP2C9 at high doses. Those on medications metabolized by these enzymes should consult a physician..
The evidence
Human clinical trials and mechanistic research support the use of Taxifolin for its primary indication. See the Research tab for full citations and study summaries.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
